Prospective, Multi-Center, Random. Study of CoStar Paclitaxel-Eluting Coronary Stent(Direct Stenting vs. Pre-Dilatation)

Exclusion Criteria

• •Known sensitivity to cobalt chromium, Paclitaxel or PLGA
• •Acute MI within 72 hours prior to the index procedure as defined by the presence of a new pathologic Q-wave, or a creatine kinase (CK) level of \> 2x the laboratory upper limits of normal and elevated MB
• •The patient is in cardiogenic shock
• •Cerebrovascular Accident (CVA) within the past 6 months
• •Acute or chronic renal dysfunction (creatinine \> 2.0 mg/dL or \> 150 µmol/L)/
• •Contraindication to ASA or to Clopidogrel
• •Thrombocytopenia (platelet count \<100,000/mm3)
• •Active gastrointestinal (GI) bleeding within the past three months
• •Any prior true anaphylactic reaction to contrast agents
• •Patient is currently taking Colchicine
• •Patient is currently, or has been treated with Paclitaxel (systemic) within12 months of the index procedure
• •Comorbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
• •Left main coronary artery disease (stenosis \>50%), whether protected or unprotected.
• •Target lesion involves a bifurcation with a diseased (\>50% stenotic) branch vessel \>2.0 mm in diameter that requires intervention.
• •Target lesion is totally occluded Thrombolysis In MI (TIMI flow ≤1).
• •The target vessel has had prior drug-eluting stent placement to vessel segment (or branch) proximal to intended target lesion site.
• •Angiographic restenosis of any segment of the target vessel that has undergone prior PCI.
• •Angiographic evidence of atherosclerotic disease with \>50% diameter stenosis (by visual estimate) proximal or distal to the target lesion (applies to the major epicardial portion of the target vessel and contiguous vessel segment if the target lesion is located in a branch vessel)